Cybin Inc. CYBN · Stock Open Cybin Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Cybin Inc. Analysis (CYBN)
Is Cybin Inc. a good investment? Cybin Inc. (CYBN) is currently trading at 8.28 USD. Market analysts have a consensus price target of 48.19 USD. This suggests a potential upside from current levels.
Investor FAQ
Does Cybin Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cybin Inc.?
Cybin Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 10, 2020 | 0.149 |
| Sept. 19, 2024 | 1:38 |
Community Discussion